Rosiglitazone Therapy of Diabetes Mellitus in Acromegaly Causes Significant Reduction of Growth Hormone and Insulin-like Growth Hormone I Secretion (CROSBI ID 133145)
Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija
Podaci o odgovornosti
Gradišer, Marina ; Matovinović, Martina ; Vrkljan, Milan
engleski
Rosiglitazone Therapy of Diabetes Mellitus in Acromegaly Causes Significant Reduction of Growth Hormone and Insulin-like Growth Hormone I Secretion
We presented woman with acromegaly and diabetes mellitus. Transsphenoidal resection of the macroadenoma confirmed histologically a GH-secreting pituitary adenoma. Since the removal of the tumor was incomplete, medical therapy was instituted. A PPAR-gama agonist was administered to treat residual diabetes.Suprisengly, there was improvement in acromegaly features with decrease levels of GH and IGF-I.
rosiglitazone; acromegaly; diabetes mellitus
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano